What is MCRB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MCRB?

P/E (TTM) is n/a and 52-week range is $2.42 to $29.98 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MCRB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MCRB?

The company profile lists revenue (TTM) near $2M, net income (TTM) near $-2.23B, EPS (TTM) near $-2.33 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Seres Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 9.7M shares outstanding, ISIN US81750R2013 when available from company profile and filing metadata.

Seres Therapeutics Inc

$MCRB

Health Care · Biotechnology

IR Run Scenarios

$2.71

+3.04%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-26. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

Employees

Website

www.serestherapeutics.com/

IPO

2015-06-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)